JP6904905B2 - 抗α４β７インテグリン抗体による治療の結果の予測 - Google Patents

抗α４β７インテグリン抗体による治療の結果の予測 Download PDF

Info

Publication number
JP6904905B2
JP6904905B2 JP2017533836A JP2017533836A JP6904905B2 JP 6904905 B2 JP6904905 B2 JP 6904905B2 JP 2017533836 A JP2017533836 A JP 2017533836A JP 2017533836 A JP2017533836 A JP 2017533836A JP 6904905 B2 JP6904905 B2 JP 6904905B2
Authority
JP
Japan
Prior art keywords
vedolizumab
patient
antibody
patients
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017533836A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018503618A5 (enExample
JP2018503618A (ja
Inventor
ロサリオ，マリア
ワイアント，ティモシー，エル．
アブヤンカー，ブリハッド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56151288&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6904905(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of JP2018503618A publication Critical patent/JP2018503618A/ja
Publication of JP2018503618A5 publication Critical patent/JP2018503618A5/ja
Priority to JP2021024874A priority Critical patent/JP7530314B2/ja
Application granted granted Critical
Publication of JP6904905B2 publication Critical patent/JP6904905B2/ja
Priority to JP2024022738A priority patent/JP2024069231A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
JP2017533836A 2014-12-24 2015-12-23 抗α４β７インテグリン抗体による治療の結果の予測 Active JP6904905B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021024874A JP7530314B2 (ja) 2014-12-24 2021-02-19 抗α４β７インテグリン抗体による治療の結果の予測
JP2024022738A JP2024069231A (ja) 2014-12-24 2024-02-19 抗α４β７インテグリン抗体による治療の結果の予測

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462096636P 2014-12-24 2014-12-24
US62/096,636 2014-12-24
US201562117750P 2015-02-18 2015-02-18
US62/117,750 2015-02-18
US201562132917P 2015-03-13 2015-03-13
US62/132,917 2015-03-13
PCT/US2015/000476 WO2016105572A1 (en) 2014-12-24 2015-12-23 PREDICTING OUTCOME OF TREATMENT WITH AN ANTI-α4β7 INTEGRIN ANTIBODY

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021024874A Division JP7530314B2 (ja) 2014-12-24 2021-02-19 抗α４β７インテグリン抗体による治療の結果の予測

Publications (3)

Publication Number Publication Date
JP2018503618A JP2018503618A (ja) 2018-02-08
JP2018503618A5 JP2018503618A5 (enExample) 2019-02-07
JP6904905B2 true JP6904905B2 (ja) 2021-07-21

Family

ID=56151288

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017533836A Active JP6904905B2 (ja) 2014-12-24 2015-12-23 抗α４β７インテグリン抗体による治療の結果の予測
JP2021024874A Active JP7530314B2 (ja) 2014-12-24 2021-02-19 抗α４β７インテグリン抗体による治療の結果の予測
JP2024022738A Pending JP2024069231A (ja) 2014-12-24 2024-02-19 抗α４β７インテグリン抗体による治療の結果の予測

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021024874A Active JP7530314B2 (ja) 2014-12-24 2021-02-19 抗α４β７インテグリン抗体による治療の結果の予測
JP2024022738A Pending JP2024069231A (ja) 2014-12-24 2024-02-19 抗α４β７インテグリン抗体による治療の結果の予測

Country Status (4)

Country Link
US (3) US20170360926A1 (enExample)
EP (1) EP3237004B1 (enExample)
JP (3) JP6904905B2 (enExample)
WO (1) WO2016105572A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
CA3295783A1 (en) 2011-05-10 2026-03-02 Prometheus Laboratories, Inc. Methods of disease activity profiling for personalized therapy management
EP3224280A1 (en) 2014-11-26 2017-10-04 Millennium Pharmaceuticals, Inc. Vedolizumab for the treatment of fistulizing crohn's disease
US9862760B2 (en) 2015-09-16 2018-01-09 Novartis Ag Polyomavirus neutralizing antibodies
MA44483A (fr) 2016-03-24 2019-01-30 Millennium Pharm Inc Procédés pour traiter des événements indésirables gastro-intestinaux d'origine immunitaire dans des traitements oncologiques immunitaires
JP7162533B2 (ja) 2016-05-04 2022-10-28 ミレニアム ファーマシューティカルズ， インコーポレイテッド 炎症性腸疾患の治療を目的とする三剤併用療法
WO2017218434A1 (en) 2016-06-12 2017-12-21 Millennium Pharmaceuticals, Inc. Method of treating inflammatory bowel disease
WO2018104893A1 (en) * 2016-12-06 2018-06-14 Glaxosmithkline Intellectual Property Development Limited Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life
IL270819B1 (en) * 2017-05-26 2026-06-01 Millennium Pharm Inc Methods for treating chronic fasciitis
KR20200009095A (ko) 2017-05-31 2020-01-29 프로메테우스 바이오사이언시즈, 인크. 크론병 환자에서 점막 치유를 평가하는 방법
JP7328960B2 (ja) * 2017-10-10 2023-08-17 プロメテウス バイオサイエンシーズ インコーポレイテッド ベドリズマブ処置をモニタリングするための方法
WO2019147824A1 (en) 2018-01-26 2019-08-01 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
EP3810085A1 (en) 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US12171764B2 (en) 2018-06-20 2024-12-24 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor
WO2019246271A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
US20230312700A1 (en) 2018-06-20 2023-10-05 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
WO2020117795A1 (en) * 2018-12-04 2020-06-11 Prometheus Biosciences, Inc. Assessment and monitoring of mucosal healing in children and adults with crohn's disease
BR112022025020A2 (pt) * 2020-06-12 2023-02-14 Vera Therapeutics Inc Dosagem de anticorpos neutralizantes de poliomavírus
CN114974595A (zh) * 2022-05-13 2022-08-30 江苏省人民医院（南京医科大学第一附属医院） 一种克罗恩病患者黏膜愈合预测模型及方法
EP4720125A1 (en) 2023-05-30 2026-04-08 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
EP4762093A1 (en) 2023-08-14 2026-06-24 Paragon Therapeutics, Inc. Alpha 4 beta 7 integrin binding proteins and methods of use
WO2025101973A1 (en) * 2023-11-09 2025-05-15 Cedars-Sinai Medical Center Systems and methods for disease classification and treatment recommendation using large language models
WO2026058045A1 (en) 2024-09-12 2026-03-19 Takeda Pharmaceutical Company Limited Alpha4beta7 inhibitor and il-23 inhibitor combination therapy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
ATE366809T1 (de) 1995-02-10 2007-08-15 Millennium Pharm Inc Addressine der schleimhaut und der blutgefässe und ihre verwendung
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US6197582B1 (en) 1998-03-18 2001-03-06 The Trustees Of Columbia University In The City Of New York Development of human monoclonal antibodies and uses thereof
US20010046496A1 (en) 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
WO2005039483A2 (en) * 2003-05-22 2005-05-06 Metaproteomics, Llc Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicity
EP1948691A1 (en) 2005-11-17 2008-07-30 Millennium Pharmaceuticals, Inc. HUMANIZED IMMUNOGLOBULIN REACTIVE WITH a4ß7INTEGRIN
EP2352762A1 (en) * 2008-11-03 2011-08-10 Schering Corporation Inflammatory bowel disease biomarkers and related methods of treatment
MX2013011130A (es) 2011-03-31 2013-10-30 Genentech Inc Metodos de administracion de antagonistas de integrina beta7.
UY34054A (es) 2011-05-02 2012-11-30 Millennium Pharm Inc FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
EP3224280A1 (en) 2014-11-26 2017-10-04 Millennium Pharmaceuticals, Inc. Vedolizumab for the treatment of fistulizing crohn's disease
CA2916283C (en) * 2015-01-09 2024-07-02 Pfizer Inc. MADCAM ANTAGONIST DOSING REGIMEN

Also Published As

Publication number Publication date
EP3237004A1 (en) 2017-11-01
WO2016105572A1 (en) 2016-06-30
JP2018503618A (ja) 2018-02-08
JP2021102612A (ja) 2021-07-15
US20240173402A1 (en) 2024-05-30
US20200155673A1 (en) 2020-05-21
US11596688B2 (en) 2023-03-07
US20170360926A1 (en) 2017-12-21
JP7530314B2 (ja) 2024-08-07
EP3237004A4 (en) 2018-06-13
EP3237004B1 (en) 2024-05-08
JP2024069231A (ja) 2024-05-21

Similar Documents

Publication Publication Date Title
JP7530314B2 (ja) 抗α４β７インテグリン抗体による治療の結果の予測
RU2625014C2 (ru) Антитела против растворимого st-2 человека и способы анализа
US11389533B2 (en) Method of treating inflammatory bowel disease
US12372524B2 (en) Anti-PAD2 antibody for treating and evaluating autoimmune and inflammatory diseases
KR20180063127A (ko) Il23 경로 바이오마커를 사용한, il23-길항제에 대한 임상 반응의 예측
KR102148063B1 (ko) 베타7 인테그린 길항제를 투여하는 방법
JP6564435B2 (ja) アルファ４ベータ７ヘテロ二量体特異抗体の投与
US20200179486A1 (en) Method of treating pediatric disorders
US20260125462A1 (en) Compounds and methods targeting interleukin-19
Steenholdt Personalized therapy with TNF-inhibitors in Crohn's disease: optimizing treatment outcomes by monitoring drug levels and anti-drug antibodies
Real-Fernández et al. Detection of anti-adalimumab antibodies in a RA responsive cohort of patients using three different techniques
US20230279095A1 (en) Methods and Treatment for Adult-Onset Still's Disease and Systemic-Onset Juvenile Idiopathic Arthritis Involving Antibodies to IL-18
Jani et al. Immunogenicity in response to biologic agents
WO2023121643A1 (en) Methods and treatment for adult-onset still's disease and systemic-onset juvenile idiopathic arthritis involving antibodies to il-18
Detrez et al. Optimising Biological Treatment for Patients with Immune-Mediated Inflammatory Diseases Exposure-Response Relation and Therapy-Related Effects
Thomsen et al. Use of infliximab and anti-infliximab antibody measurements to evaluate and optimize efficacy and safety of infliximab maintenance therapy in Crohn's disease
Oladapo Medication adherence, persistence, switching and dose escalation with the use of tumor necrosis factor (TNF) inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181219

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181219

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20190611

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20190613

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191126

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200226

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200420

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200526

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20201020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210219

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210219

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20210309

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210413

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210420

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210601

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210624

R150 Certificate of patent or registration of utility model

Ref document number: 6904905

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250